acut
viral
respiratori
tract
infect
arti
also
known
common
cold
preval
diseas
human
usa
alon
noninfluenza
cold
annual
account
million
doctor
visit
million
lost
school
work
day
total
econom
impact
approxim
billion
arti
among
ten
expens
ill
societi
major
case
common
cold
caus
respiratori
virus
rhinoviru
coronaviru
parainfluenza
influenza
respiratori
syncyti
viru
adenoviru
enteroviru
metapneumoviru
number
etiolog
agent
antigen
variabl
limit
possibl
creat
effect
vaccin
common
cold
numer
attempt
find
effect
prophylact
therapeut
treatment
includ
pharmaceut
herbal
product
vitamin
zinc
other
provid
controversi
result
consid
effect
systemat
review
present
therapi
common
cold
mainli
includ
gener
care
treatment
symptom
measur
reduc
symptom
therapeut
intervent
date
proven
effect
reduc
viral
load
durat
sever
common
cold
concept
use
sulphat
polysaccharid
antivir
agent
introduc
year
ago
due
high
molecular
weight
polym
parenter
administr
feasibl
treatment
sexual
transmit
diseas
research
focus
topic
microbicid
develop
although
enough
evid
accumul
recommend
agent
present
howev
polysaccharid
test
prevent
sexual
transmit
viral
infect
compon
spermicid
recent
shown
iotacarrageenan
sulphat
polysaccharid
found
speci
red
seawe
potent
antivir
agent
respiratori
virus
cell
cultur
anim
model
laboratori
data
show
carrageenanpolym
bind
directli
viru
cell
trap
particl
prevent
cell
attach
thu
carrageenan
interfer
viru
life
cycl
earli
stage
due
physic
mechan
action
studi
vitro
vivo
shown
effect
carrageenan
sever
virus
hrv
influenza
rsv
test
vitro
shown
carrageenan
penetr
mucosa
therefor
pharmacolog
immunolog
metabol
activ
carrageenan
expect
addit
preclin
studi
symptomat
benefit
antivir
efficaci
nasal
spray
contain
carrageenan
shown
two
random
clinic
trial
adult
pediatr
patient
common
cold
studi
design
investig
efficaci
carrageenancontain
nasal
spray
durat
common
cold
viral
load
nasal
fluid
adult
patient
patient
recruit
depart
otorhinolaryngolog
vienna
gener
hospit
austria
januari
april
elig
patient
adult
year
older
earli
symptom
common
cold
onset
less
hour
inclus
mild
moder
intens
total
symptom
score
tss
intens
common
cold
symptom
assess
accord
publish
score
system
patient
score
eight
main
symptom
headach
muscl
ach
chilli
sore
throat
block
nose
runni
nose
cough
sneez
use
four
point
scale
follow
symptom
absent
repres
mild
moder
sever
intens
respect
tss
calcul
investig
sum
individu
score
main
exclus
criteria
known
hypersensit
allergi
compon
test
product
concomit
diseas
infect
could
interfer
particip
studi
reason
nasal
obstruct
past
present
condit
treatment
could
influenc
symptom
score
specif
treatment
period
day
use
nasal
spray
nonsteroid
antiinflammatori
drug
antihistamin
decongest
corticosteroid
antivir
antituss
herbal
combin
common
cold
supplement
contain
mg
zinc
mg
vitamin
c
prohibit
studi
perform
complianc
ich
note
guidanc
good
clinic
practic
cpmp
ich
principl
declar
helsinki
ethic
committe
particip
site
approv
protocol
amend
written
inform
consent
obtain
particip
enrol
studi
particip
compens
expens
associ
particip
singlecent
doubleblind
parallelgroup
placebocontrol
random
clinic
trial
show
differ
carrageenancontain
nasal
spray
placebo
adult
patient
earli
symptom
common
cold
object
trial
obtain
inform
efficaci
carrageenancontain
nasal
spray
coldamari
prophylact
adult
patient
earli
symptom
common
cold
aim
show
least
day
reduct
durat
diseas
standard
deviat
sd
result
sampl
size
per
group
maxim
dropout
rate
expect
sampl
size
set
patient
per
group
typei
error
probabl
set
twosid
alpha
power
set
percent
patient
randomli
assign
receiv
either
coldamari
prophylact
nasal
spray
contain
carrageenan
salin
solut
sodium
chlorid
gl
nasal
spray
serv
placebo
nasal
spray
administ
three
time
daili
nostril
day
coldamari
prophylact
nasal
spray
regist
medic
devic
market
austria
manufactur
mono
chem
gmbh
austria
subject
randomis
one
two
group
accord
random
schedul
use
random
permut
block
block
size
random
list
prepar
third
parti
unblind
trial
review
data
base
lock
nasal
spray
threedigit
code
spray
assign
investig
consecut
start
lowest
treatment
number
avail
investig
patient
blind
studi
treatment
carrageenan
placebo
nasal
spray
ident
shape
size
colour
spray
solut
clear
colourless
odourless
free
particul
enrol
subject
medic
histori
evalu
baselin
clinic
assess
includ
ear
nose
throat
examin
perform
nasal
wash
fluid
laboratori
test
viral
assess
obtain
ent
examin
nasal
wash
fluid
collect
repeat
day
visit
visit
visit
safeti
evalu
also
conduct
last
visit
day
addit
final
safeti
assess
subject
question
regard
opinion
accept
studi
treatment
day
patient
record
whether
use
nasal
spray
instruct
presenc
addit
symptom
use
addit
treatment
score
main
common
cold
symptom
describ
diari
return
studi
site
visit
day
patient
kept
diari
daili
basi
record
common
cold
symptom
experienc
product
dosag
treatment
taken
complianc
studi
treatment
assess
measur
weight
dispens
nasal
spray
day
issuanc
return
differ
less
g
assess
consumpt
less
studi
protocol
patient
subsequ
exclud
pp
analysi
nasal
wash
fluid
sampl
obtain
virolog
analysi
baselin
day
visit
studi
day
visit
studi
day
use
follow
procedur
approxim
ml
salin
solut
instil
nostril
kept
nose
second
patient
requir
lean
head
forward
allow
salin
drip
nose
collect
cup
collect
mucu
remov
sampl
divid
cryovial
label
store
assess
presenc
amount
viral
rna
nasal
wash
fluid
sampl
identifi
use
realtim
quantit
rtpcr
assay
describ
previous
analys
respiratori
virus
rhinoviru
coronaviru
type
coronaviru
type
influenza
viru
type
b
human
metapneumoviru
respiratori
syncyti
viru
parainfluenza
type
perform
patient
consid
virusposit
least
one
nasal
wash
fluid
sampl
test
posit
one
viru
primari
efficaci
variabl
durat
diseas
defin
time
last
day
symptom
follow
day
studi
period
without
symptom
main
secondari
efficaci
variabl
presenc
cold
virus
nasal
fluid
sampl
sever
common
cold
symptom
separ
studi
day
number
day
without
symptom
observ
period
use
comed
addit
studi
treatment
day
finish
treatment
carrageenan
nasal
spray
number
clear
newli
acquir
viral
infect
observ
period
cours
studi
prior
unblind
data
perform
analysi
follow
efficaci
outcom
adapt
base
result
obtain
previou
common
cold
trial
primari
efficaci
paramet
chang
time
period
first
last
day
symptom
follow
hour
without
symptom
time
period
first
last
day
symptom
follow
day
without
symptom
definit
use
anoth
studi
carrageenan
pediatr
popul
due
physic
mechan
action
test
polym
patient
cold
viru
nasal
caviti
like
benefit
local
antivir
treatment
iotacarrageenan
henc
analysi
effect
carri
patient
laboratori
confirm
cold
viru
infect
figur
therefor
intentiontotreat
viru
posit
popul
ittvp
well
per
protocol
viru
posit
popul
ppvp
assess
analysi
safeti
data
patient
receiv
studi
medic
includ
itt
protocol
amend
includ
primari
endpoint
assess
viru
posit
popul
approv
local
ethic
committe
prior
unblind
studi
primari
end
point
analys
use
log
rank
test
mantelhaenzel
test
data
set
check
normal
distribut
kolmogorovsmirnovtest
prior
analysi
binari
categor
data
eg
presenc
absenc
virus
number
patient
advers
event
ae
analys
chisquar
test
viral
titer
nasal
wash
fluid
well
chang
titer
visit
analys
use
median
test
due
high
variabl
dataset
analysi
virus
detect
includ
viru
account
individu
sinc
patient
one
viru
number
viral
event
higher
number
infect
patient
experi
previou
trial
suggest
tss
data
might
normal
distribut
lopsid
confirm
actual
studi
kolmogorovsmirnov
test
test
lopsid
distribut
data
henc
analysi
tss
standard
convent
method
applic
prior
unblind
decid
appli
analysi
rewumod
regress
unknown
model
domain
addit
file
figur
techniqu
instead
convent
statist
method
principl
techniqu
describ
detail
previous
briefli
model
transform
tss
valu
baselin
day
two
line
regress
model
individu
patient
averag
paramet
two
line
allow
comparison
cours
diseas
treatment
group
irrespect
absolut
tss
valu
rewumod
analysi
yield
reduct
ten
individu
data
point
tss
valu
five
relev
paramet
intercept
slope
first
straight
line
paramet
repres
cours
earli
phase
diseas
estimatedcalcul
break
point
bp
two
line
repres
time
point
chang
cours
diseas
paramet
second
line
abbrevi
repres
cours
later
phase
diseas
reason
rewumod
model
less
sensit
absolut
score
valu
allow
evalu
differ
cours
diseas
independ
absolut
valu
find
screen
visit
document
ae
except
symptom
attribut
common
cold
sneez
runni
nose
nasal
obstruct
sore
throat
cough
headach
fatigu
chilli
defin
protocol
nevertheless
symptom
mark
intens
deem
relat
studi
diseas
record
ae
altogeth
patient
suspect
common
cold
random
complet
treatment
itt
popul
reason
patient
exclus
lost
followup
patient
exclus
accord
protocol
patient
none
patient
discontinu
treatment
due
advers
event
figur
pp
popul
consist
patient
main
reason
exclus
use
prohibit
medic
n
noncompli
n
addit
one
patient
enrol
violat
inclusionexclus
criteria
chronic
obstruct
pulmonari
diseas
concomit
diseas
viru
posit
popul
consist
patient
ittvp
patient
ppvp
group
figur
itt
popul
compris
femal
placebo
carrageenan
male
placebo
carrageenan
mean
age
year
placebo
year
carrageenan
group
statist
signific
differ
demograph
variabl
smoke
statu
intens
symptom
treatment
group
ittittvp
tabl
ppppvp
data
shown
popul
total
patient
itt
popul
laboratori
confirm
infect
least
one
common
cold
viru
signific
differ
viru
distribut
group
total
number
virusposit
patient
per
treatment
group
well
number
patient
infect
specif
virus
shown
tabl
influenza
viru
b
parainfluenza
viru
type
detect
patient
patient
test
posit
one
viru
nasal
fluid
patient
laboratori
confirm
cold
viru
infect
analysi
logrank
test
show
faster
recoveri
iotacarrageenan
treat
patient
compar
placebo
ppvp
popul
estim
durat
diseas
day
confid
interv
ci
day
carrageenan
group
compar
day
ci
day
placebo
group
logrank
test
p
figur
rel
risk
iotacarrageenan
treat
ppvp
patient
reduc
symptom
day
ci
absolut
risk
reduct
arr
ci
number
need
treat
nnt
ci
similar
trend
observ
ittvp
popul
howev
differ
statist
signific
logrank
test
p
figur
appli
log
rank
test
sensit
ratio
hazard
higher
earli
surviv
time
clearli
case
studi
analysi
mantelhaenszel
test
reveal
slightli
differ
pvalu
chang
overal
result
ittvp
p
ppvp
p
rel
risk
iotacarrageenan
treat
ittvp
patient
reduc
symptom
day
ci
arr
ci
number
need
treat
nnt
ci
itt
popul
n
statist
signific
durat
diseas
observ
analysi
tss
use
rewumod
virusposit
popul
ittvp
ppvp
show
statist
signific
differ
group
earli
phase
diseas
howev
ittvp
popul
break
point
achiev
carrageenan
group
day
earlier
mean
day
carrageenan
arm
compar
mean
day
placebo
arm
p
possibl
repres
earlier
start
recoveri
phase
follow
signific
faster
reduct
symptom
intens
carrageenan
group
mean
tss
decreas
pointsday
carrageenan
group
compar
mean
pointsday
placebo
group
p
figur
second
phase
diseas
similar
result
also
observ
ppvp
patient
break
point
observ
earlier
carrageenan
group
mean
day
carrageenan
compar
mean
day
placebo
p
follow
faster
decreas
tss
second
phase
diseas
mean
tss
decreas
pointsday
carrageenan
group
compar
pointsday
placebo
group
p
figur
itt
n
differ
breakpoint
observ
second
phase
diseas
tss
decreas
pointsday
carrageenan
group
compar
pointsday
placebo
group
p
posthoc
analysi
symptom
data
reveal
ittvp
popul
patient
reappear
symptom
placebo
patient
carrageenan
patient
differ
group
signific
pvalu
overal
number
patient
take
medic
common
cold
symptom
low
less
total
patient
carrageenan
group
patient
placebo
group
take
addit
medic
itt
studi
period
pp
popul
patient
carrageenan
group
compar
patient
placebo
group
consum
addit
medic
differ
group
repres
trend
statist
signific
p
nasal
fluid
carrageenan
placebo
patient
viral
titer
decreas
visit
visit
howev
carrageenan
treat
patient
show
significantli
greater
decreas
viral
titer
visit
visit
figur
ittvp
popul
median
decreas
viral
titer
carrageenan
group
compar
placebo
group
p
figur
ppvp
popul
figur
carrageenan
placebo
group
respect
p
figur
median
titer
visit
day
patient
group
analysi
perform
overal
studi
treatment
well
toler
statist
signific
differ
found
studi
group
regard
total
number
distribut
ae
total
ae
relat
relat
report
involv
subject
subject
treatment
group
trial
signific
differ
frequenc
ae
treatment
group
major
ae
observ
twice
per
soc
system
organ
class
categori
correspond
frequenc
one
ae
placebo
group
feel
burn
nose
consid
relat
studi
treatment
investig
vast
major
ae
mild
intens
one
ae
carrageenan
group
cycl
accid
cerebr
commot
subarachnoid
hemorrhag
moder
intens
one
ae
placebo
group
gastric
hypermotil
rate
sever
studi
sever
ae
patient
relat
resolv
end
studi
report
carrageenan
group
none
patient
discontinu
treatment
particip
trial
due
ae
doubl
blind
placebo
control
trial
evalu
effect
carrageenan
nasal
spray
treatment
adult
patient
common
cold
symptom
studi
confirm
result
earlier
studi
adult
children
patient
compliant
protocol
posit
cold
viru
infect
reduct
diseas
durat
day
observ
result
therefor
confirm
local
antivir
effect
carrageenan
lead
signific
clinic
benefit
pronounc
trend
also
observ
ittvp
popul
although
differ
reach
level
statist
signific
main
differ
ittvp
ppvp
popul
use
concomit
medic
studi
patient
exclud
pp
analysi
due
insuffici
use
studi
medic
reduct
dosag
correspond
day
treatment
document
thu
conclud
test
dosag
time
per
day
necessari
fewer
applic
may
lead
reduc
clinic
benefit
mention
materi
method
section
primari
endpoint
chang
cours
studi
prior
unblind
approv
ethic
committe
base
result
earlier
studi
children
analysi
durat
diseas
accord
endpoint
time
period
first
last
day
symptom
follow
hour
without
symptom
result
signific
differ
analys
popul
neither
adult
children
henc
conclud
part
posit
effect
iotacarrageenan
treatment
base
abil
prevent
reappear
symptom
symptom
free
period
longer
hour
result
report
limit
patient
test
posit
realtim
pcr
studi
popul
analysi
primari
endpoint
complet
studi
popul
itt
n
reveal
signific
differ
iotacarrageenan
placebo
group
howev
analysi
tss
use
rewumod
reveal
signific
faster
reduct
symptom
second
phase
diseas
similar
ittvp
group
reduct
symptom
iotacarrageenan
group
approxim
doubl
compar
placebo
group
result
indic
independ
actual
caus
symptom
iotacarrageenan
treatment
result
faster
reduct
symptom
sever
due
physic
mechan
action
carrageenan
unlik
patient
cold
symptom
caus
viru
would
ad
benefit
comparison
placebo
treatment
salin
nasal
solut
treatment
common
cold
salin
nasal
irrig
discuss
clinic
benefit
describ
associ
less
time
work
consequ
current
studi
limit
fact
placebo
nasal
spray
contain
salin
nasal
solut
like
caus
clinic
benefit
well
could
explain
signific
effect
primari
endpoint
itt
popul
observ
trial
contrast
viru
posit
popul
compris
viru
posit
patient
recent
studi
children
similar
design
reveal
signific
reduct
time
diseas
clearanc
day
itt
popul
compar
studi
children
trial
around
children
test
virusposit
henc
neglig
differ
itt
ittvp
popul
although
also
studi
ittvp
popul
experienc
stronger
effect
treatment
carrageenan
assum
adult
children
infect
common
cold
virus
benefit
local
applic
carrageenan
similar
way
adult
effect
diseas
durat
might
mask
patient
cold
symptom
caus
viral
infect
howev
faster
rate
symptom
reduct
iotacarrageenan
treat
adult
suggest
patient
cold
symptom
ad
benefit
compar
standard
salin
nasal
spray
serv
placebo
trial
analysi
tss
show
faster
symptom
improv
carrageenan
treat
patient
second
phase
diseas
statist
signific
differ
ittvp
ppvp
group
addit
break
point
repres
chang
cours
diseas
start
recoveri
earlier
ittvp
ppvp
carrageenan
patient
appli
rewumod
method
allow
evalu
differ
cours
diseas
independ
absolut
valu
particular
interest
absolut
valu
depend
differ
pathogen
subject
patient
assess
signific
differ
tss
carrageenan
placebo
group
observ
first
day
studi
howev
carrageenan
treat
patient
experienc
significantli
earlier
improv
diseas
symptom
furthermor
rate
symptom
reduct
per
day
approxim
doubl
therefor
conclud
signific
reduct
time
diseas
clearanc
achiev
faster
decreas
symptom
visibl
day
inclus
result
line
data
trial
conduct
adult
show
signific
benefit
tss
rel
small
group
patient
trial
conduct
eccl
et
al
show
within
first
two
day
inclus
patient
report
improv
symptom
score
howev
start
day
carrageenan
treat
patient
report
greater
reduct
tss
placebo
patient
result
signific
clinic
benefit
signific
reduct
tss
day
clinic
relev
find
support
fact
symptom
score
day
carrageenan
treat
patient
level
placebo
treat
patient
day
indic
reduct
time
symptom
allevi
day
compar
well
day
reduct
obtain
trial
similar
studi
natur
common
cold
trial
limit
uncertainti
actual
date
time
diseas
onset
potenti
inclus
patient
later
stage
diseas
could
sourc
bia
diminish
treatment
efficaci
natur
set
compar
result
studi
natur
experiment
cold
suggest
substanti
proport
patient
natur
cold
suffer
symptom
day
longer
report
furthermor
one
studi
analysi
patient
record
reveal
patient
natur
cold
report
sick
hour
inclus
criteria
fact
ill
day
antimicrobi
antivir
intervent
earli
start
treatment
carrageenan
like
provid
best
benefit
patient
rate
exposur
cigarett
smoke
trial
high
tabl
emerg
evid
suggest
cigarett
smoke
affect
viral
bacteri
bind
epitheli
cell
post
hoc
analysi
conduct
reveal
whether
iotacarrageenan
treatment
benefici
patient
expos
cigarett
smoke
iotacarrageenan
treat
patient
ittvp
smoke
expos
popul
includ
smoker
smoke
expos
show
estim
durat
diseas
day
confid
interv
ci
day
carrageenan
group
compar
day
ci
day
placebo
group
logrank
test
p
compar
gener
popul
interest
smoke
expos
iotacarrageenan
treat
patient
shorter
durat
diseas
differ
placebo
group
trial
neither
design
power
demonstr
effect
particular
subgroup
henc
encourag
result
need
view
caution
secondari
object
studi
determin
viral
pathogen
intranas
viral
load
analysi
nasal
fluid
sampl
yield
seven
differ
respiratori
virus
tabl
expect
common
cold
patient
viru
posit
patient
suffer
rhinoviru
corona
viru
infect
viral
titer
carrageenan
placebo
treat
group
decreas
baselin
second
visit
day
result
expect
natur
cours
common
cold
howev
magnitud
reduct
greater
patient
receiv
carrageenan
nasal
spray
statist
signific
itt
pp
popul
data
correspond
result
two
earlier
clinic
trial
adult
children
reveal
signific
reduct
viral
load
nasal
secret
carrageenan
patient
trial
intranas
treatment
carrageenan
nasal
spray
safe
drug
relat
seriou
advers
event
detect
like
attribut
physic
mechan
action
fact
carrageenan
capabl
cell
invas
due
presum
low
rate
seriou
advers
event
studi
insuffici
power
detect
use
carrageenan
nasal
spray
associ
signific
reduct
viral
load
nasal
fluid
common
cold
patient
laboratori
confirm
cold
viru
compliant
studi
treatment
show
shorter
durat
diseas
faster
reduct
common
cold
symptom
treat
carrageenan
furthermor
use
carrageenan
nasal
spray
safe
well
toler
appropri
dosag
seem
essenti
earli
intervent
suggest
result
signific
clinic
effect
therefor
iotacarrageenan
may
good
altern
treatment
viral
infect
upper
respiratori
tract
known
common
cold
grassauer
e
prieschlgrassau
hold
manag
posit
marinom
biotechnologi
gmbh
studi
sponsor
bodenteich
full
time
employe
marinom
biotechnologi
gmbh
k
neumann
compens
work
statist
analysi
marinom
biotechnologi
gmbh
lion
receiv
reimburs
perform
molecular
analysi
marinom
biotechnologi
gmbh
ml
perform
studi
site
draft
manuscript
ee
ss
particip
data
acquisit
mr
tl
carri
molecular
analysi
kn
particip
design
studi
perform
statist
analysi
epg
ag
ab
particip
design
coordin
studi
cam
conceiv
studi
particip
design
coordin
help
draft
manuscript
author
read
approv
final
manuscript
